Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel nanoformulation - DFB Soria/NanOlogy

Next Previous
X
Search
Drug Profile

Paclitaxel nanoformulation - DFB Soria/NanOlogy

Alternative Names: Large surface area microparticle-paclitaxel; LSAM-Pac - DFB Soria/NanOlogy; LSAM-PTX; NanoPac; Nanotax; SOR 007; Submicron particle paclitaxel - DFB Soria/NanOlogy

Latest Information Update: 21 Dec 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DFB Soria; Nanology
  • Developer bioskin; DFB Soria; NanOlogy; US Biotest Inc
  • Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Actinic keratosis; Lung cancer; Ovarian cancer; Pancreatic cancer; Pancreatic disorders; Prostate cancer
  • Phase I/II Skin cancer
  • No development reported Cervical intraepithelial neoplasia; Non-small cell lung cancer; Peritoneal cancer; Plaque psoriasis

Most Recent Events

  • 19 Dec 2023 Updated efficacy and adverse events data from a phase IIa trial in Lung cancer released by NanOlogy
  • 28 Nov 2023 Nanology completes the phase II trial in Lung cancer(Adjunctive treatment) in USA (Intratumoural) (NCT04314895)
  • 10 Oct 2023 Initial Adverse events and efficacy data from the phase II trial in Pancreatic cancer released by NanOlogy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top